laquinimod laquinimod laquinimod is an experimental immunomodulator developed by active biotech and teva. it is being investigated as an oral treatment for multiple sclerosis (ms). laquinimod names preferred iupac name 5-chloro-n-ethyl-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide identifiers cas number 248281-84-7 n 3d model (jsmol) interactive image chembl chembl66092 y chemspider 11444966 y echa infocard 100.220.145 iuphar/bps 7639 pubchem cid 216469 unii 908sy76s4g y comptox dashboard (epa) dtxsid30179536 inchi inchi=1s/c19h17cln2o3/c1-3-22(12-8-5-4-6-9-12)19(25)16-17(23)15-13(20)10-7-11-14(15)21(2)18(16)24/h4-11,23h,3h2,1-2h3 ykey: gkwpceffihsjoe-uhfffaoysa-n yinchi=1/c19h17cln2o3/c1-3-22(12-8-5-4-6-9-12)19(25)16-17(23)15-13(20)10-7-11-14(15)21(2)18(16)24/h4-11,23h,3h2,1-2h3key: gkwpceffihsjoe-uhfffaoyaw smiles ccn(c1ccccc1)c(=o)c\3=c(/o)c2c(cl)cccc2n(c)c/3=o properties chemical formula c19h17cln2o3 molar mass 356.803 g/mol pharmacology atc code n07xx10 (who) except where otherwise noted, data are given for materials in their standard state (at 25 °c , 100 kpa). n verify (what is yn ?) infobox references laquinimod is the successor of active biotech's failed experimental immunomodulator linomide. the compound has been investigated in two phase ii trials using successive magnetic resonance scans (mri). laquinimod seems to be able to reduce the ms disease activity on mri. however, the response to a given dose was discrepant between both studies. phase iii studies for ms started in december 2007. in 2011, teva announced its clinical trials involving laquinimod had failed, being unable to significantly reduce relapses in ms among patients beyond a placebo. however, the final results of above-mentioned phase iii trial proved oral laquinimod administered once daily slowed the progression of disability and reduced the rate of relapse in patients with relapsing–remitting multiple sclerosis. on may 7, 2013 laquinimod was approved by the russian ministry of health (the fda analog) as a treatment for relapsing-remitting multiple sclerosis (rrms) under the brand name nerventra.